ClinicalTrials.gg
CompletedNCT06234956Updated Nov 17, 2026

Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.

A Phase 2 interventional study of BIMERVAX in SARS CoV 2 Infection, sponsored by Hipra Scientific, S.L.U. Completed at 7 sites in Spain. Open to participants aged 12 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hipra Scientific, S.L.U · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2023, registered Oct 2023).
Updated Nov 17, 2026Title changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
242
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.

Enrollment
93rd of 254
242 · median 132
Started
2023
with 21 others
Phase 2
54 of 401
1 open now
Registered
375th of 401
by date
Lead sponsor
7 of 401
Hipra Scientific, S.L.U

Among the 401 studies in COVID-19 with a site in Spain, this one is the 93rd largest by enrollment of the 254 interventional ones that give a count, is one of 22 that started in 2023, is one of 54 in phase 2, and was the 375th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in COVID-19 with a site in Spain, or all of them as a file.
02

Study summary

This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.

Read the detailed description

This was a Phase IIb, open-label, single-agent, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.

In this study a total of 300 adolescents from 12 to less than 18 years old were to be enrolled and followed for 12 months.

The immunogenicity was to be evaluated in at least 154 adolescents with no documented medical history of SARS-CoV-2 infection, who had previously received two doses of Comirnaty® vaccine.

The safety assessment was to be evaluated in at least 300 adolescents who had previously received two doses of Comirnaty® vaccine.

All participants received a single heterologous booster dose of BIMERVAX®, at least 6 months after their second dose of Comirnaty® vaccine.

03

Conditions studied

  • SARS CoV 2 Infection

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents aged from 12 to less than 18 years at Screening.
  • Participant's parent(s)/legal guardian(s) willing and able to sign the and can comply with all study visits and procedures. A written assent will be required for all participants in the study. Note: Participants are expected to be available for the duration of the study and whose parent(s)/legal guardian can be contacted by telephone during study participation.
  • Participant must have received two previous doses of Comirnaty, last dose being at least 6 months before screening.
  • Participant has a at or above the third percentile according to local Child Growth Standards at Screening Visit.
  • Healthy participants and participants with pre-existing, chronic and stable diseases (non-), if these are stable and well-controlled according to the investigator's judgment, are eligible for inclusion in the study. Note: Healthy participants are determined by medical history, physical examination, and clinical judgment of the investigator. Healthy participants with pre-existing stable diseases, are defined as diseases not requiring significant change in the therapy or hospitalisation for worsening disease during the 6 weeks before enrolment.
  • Has a negative Rapid Antigen Test (RAT) at Day 0 before BIMERVAX® vaccine administration.
  • Participants biologically able to have children may be enrolled in the study if the participant fulfils all the following criteria:
  • Has a negative urine pregnancy test at Screening (Day 0), only for those participants who are biologically able to become pregnant.
  • Has practiced adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to the booster dose, only for those participants who are biologically able to become pregnant.
  • Has agreed to continue adequate contraception or abstinence through 3 months following the booster dose.

    1. Participants with female reproductive system:

      1. Hormonal contraception (progestogen only or combined: oral, injectable or transdermal (patch)
      2. Intrauterine device.
      3. Vasectomized partner (the vasectomized partner should be the sole partner for that participant).
      4. Condom.
    2. Participants with male reproductive system:

      1. Vasectomized participants.
      2. Agree to use a condom in partners biologically able to become pregnant.
  • Participant must have a body weight >50 kg at Screening visit to be eligible for the cellular immunology assays.

Exclusion criteria

Exclusion Criteria:

  • Acute illness with fever ≥ 38.0°C at Screening or within 24 hours prior to vaccination. Participant can be rescheduled for Screening when they have completed 24 hours without fever. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
  • Received medications intended to prevent or treat COVID-19 before Screening, except for Comirnaty vaccines.
  • Previous or current diagnosis of MIS-C.
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

Note: This includes both conditions that may increase the risk associated with study intervention administration or a condition that may interfere with the interpretation of study results.

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s).
  • individuals defined as those with primary and secondary immune deficiencies and those receiving chemotherapy or immunosuppressant drugs other than and glucocorticoids (maximum 1 mg/kg/day of prednisone or total dose of 20mg/day by any administration route for a maximum of 30 consecutive days), within 90 days prior to vaccination or during the study.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Female who is pregnant or breastfeeding.
  • Receipt of blood/plasma products, immunoglobulin, monoclonal antibodies, or receipt of any passive antibody therapy, within 90 days prior to vaccination or during the study.
  • Participation in other studies involving study intervention within 28 days prior to screening and/or during study participation.
  • Received any non-study vaccine (including seasonal Influenza vaccine) within 14 days before or after screening. For live or attenuated vaccines, 4 weeks before or after screening.
  • History of illegal substance use or alcohol abuse within the past 2 years.
  • History of a diagnosis or other conditions that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
  • Individuals who are family members of the Investigators.
  • Individuals with documented medical history of microbiologically confirmed COVID-19 will not be eligible for the immunogenicity group.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    BIMERVAX

    One dose of 40μg of BIMERVAX, administered intramuscularly

    Biological: BIMERVAX

Interventions

  • BiologicalBIMERVAX

    One dose of 40μg of BIMERVAX, administered intramuscularly

06

What researchers measure

Primary outcomes

  1. Changes in immunogenicity against Omicron BA.1

    Neutralisation titre against Omicron BA.1 measured as inhibitory concentration 50 (IC50) by PBNA and reported as log10 concentration for each individual sample at Baseline and Day 14.

    Time frame: 14 days

  2. Changes in immunogenicity against Omicron BA.1

    Geometric Mean Titre (GMT) for group comparison with HIPRA-HH-2 at Baseline and Day 14.

    Time frame: 14 days

  3. Incidence of solicited local and systemic reactions (Safety and tolerability of PHH-1V)

    Solicited local and systemic reactions through Day 7 after vaccination.

    Time frame: 7 days

  4. Incidence of unsolicited local and systemic adverse events (Safety and tolerability of PHH-1V)

    Unsolicited local and systemic adverse events (AEs) through Day 28 after vaccination.

    Time frame: 28 days

  5. Incidence of related adverse events and serious adverse events (Safety and tolerability of PHH-1V)

    Related adverse events (AEs) and all serious adverse events (SAEs) through the end of the study.

    Time frame: 1 year

  6. Incidence of adverse events of special interest (Safety and tolerability of PHH-1V)

    Adverse event of special interest (AESI) through the end of the study.

    Time frame: 1 year

  7. Incidence of related medically attended adverse events (Safety and tolerability of PHH-1V)

    Related medically attended adverse events (MAAE) through the end of the study.

    Time frame: 1 year

  8. Incidence of Grade 2, Grade 3 and Grade 4 changes in safety laboratory parameters (Safety and tolerability of PHH-1V)

    Grade 2, Grade 3 and Grade 4 changes from Baseline in safety laboratory parameters through Day 14 after vaccination.

    Time frame: 14 days

Secondary outcomes

  1. Changes in immunogenicity against VOCs

    Neutralisation titre against VOCs (at least Beta and Delta) measured as IC50 by PBNA and reported as log10 concentration for each individual sample at Baseline and Days 14, 84, 168 and 336.

    Time frame: Days 14, 84, 168 and 336

  2. Changes in immunogenicity against VOCs

    GMT at Baseline and Days 14, 84, 168 and 336.

    Time frame: Days 14, 84, 168 and 336

  3. Changes in immunogenicity against Omicron BA.1 and VOCs

    GMFR in neutralising antibodies titres against Omicron BA.1 and VOCs (at least Beta and Delta) at Baseline and Day 14.

    Time frame: Day 14

07

Study locations

7 sites
  • Hospital Vall Hebron
    Barcelona, Barcelona 08035, Spain
  • CAP Centelles
    Centelles, Barcelona 08540, Spain
  • Hospital Josep Trueta
    Girona, Girona 17007, Spain
  • CAP Peralada
    Peralada, Girona 17491, Spain
  • Hospital HM Montepríncipe
    Boadilla del Monte, Madrid 28660, Spain
  • Hospital La Paz
    Madrid, Madrid 28046, Spain
  • Hospital HM Puerta del Sur
    Móstoles, Madrid 28938, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Sep 2025, 27 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 27 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Jan 31, 2024
StartActual
Jun 8, 2023
Primary completionActual
Sep 9, 2025
CompletionActual
Sep 9, 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Title Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
    + 4 other changes: verification date, description, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06234956
Lead sponsor
Hipra Scientific, S.L.U
Collaborators
Veristat, Inc., VHIR, Asphalion
Responsible party
Sponsor
First posted
Jan 31, 2024
Start date
Jun 8, 2023
Primary completion
Sep 9, 2025
Completion
Sep 9, 2025
Last update
Nov 17, 2026

Study contacts

Teresa Prat
study director · Hipra Scientific, S.L.U

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion